Millennium Management’s Soleno Therapeutics SLNO Stock Holding History

Millennium Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,000	Closed	-$324K	–	6325
2025 Q4	$324K	Sell	7,000 -61,700	-90%	-$3.38M	﹤0.01%	5218
2025 Q3	$4.64M	Buy	68,700 +43,700	+175%	+$3.24M	﹤0.01%	3219
2025 Q2	$2.09M	Sell	25,000 -40,000	-62%	-$2.99M	﹤0.01%	3839
2025 Q1	$4.64M	Buy	65,000 +50,000	+333%	+$2.43M	﹤0.01%	2936
2024 Q4	$674K	Buy	+15,000	New	+$777K	﹤0.01%	4514

Other funds holding SLNO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Millennium Management's SLNO Position: Q1 2026 in Review

Millennium Management reduced its Soleno Therapeutics (SLNO) stake by 51% in Q1 2026, selling an estimated $24.7M and leaving 606,513 shares worth $20.3M. The position accounts for 0.01% of the portfolio, ranked #1536.

Millennium Management first reported a position in SLNO in Q1 2020 and has held it in 17 quarters since. The position peaked at $66.2M in Q3 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Millennium Management held 606,513 shares of Soleno Therapeutics worth $20.3M as of Q1 2026.
Millennium Management sold 629,808 Soleno Therapeutics shares in Q1 2026, an estimated $24.7M.
Soleno Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1536 holding.
Millennium Management first reported a position in Soleno Therapeutics in Q1 2020 and has held it in 17 quarters since.
Millennium Management's Soleno Therapeutics position peaked at $66.2M in Q3 2025.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.